Securities Class Action Hits POET Technologies (POET), Fire-Apparatus Antitrust Theory Spreads from REVG to Oshkosh (OSK), Novo Nordisk (NVO) GLP-1 Docket Adds Four More

Executive Summary

As of April 29, 2026, The Litigation Alpha Desk has identified 59 new federal civil filings for the April 23-28 trading window — a +15.7% step-up from the 51 logged in our April 28 edition — anchored by the first pure Section 10(b) securities class action of the week: Jones v. POET Technologies Inc. in the District of New Jersey (CourtListener docket 73259670, filed April 28, 2026). POET Technologies (NASDAQ: POET; TSXV: PTK) is a photonic-integrated-circuit micro-cap in the AI optical-interconnect supply chain; a securities-fraud class action against this thematic exposure is the single highest-conviction tradeable event of the week. The Nature-of-Suit code (850 Securities/Commodities) and the venue (D.N.J., a known plaintiff-bar staging ground for tech micro-caps) elevate structural severity to 8/10 pending docket-text confirmation.

The second major signal is a structural broadening of the fire-apparatus antitrust theory flagged on April 28. Following last week's three-city REV Group, Inc. (NYSE: REVG) cluster, The Durango Fire Protection District v. Oshkosh Corporation (NYSE: OSK) filed in E.D. Wisconsin on April 28, 2026 (Docket 73257708, NoS 410), alleging anticompetitive conduct against the second of the two dominant U.S. fire-apparatus OEMs. The pivot from REVG-only to REVG + OSK in the same district is the textbook precursor to JPML §1407 consolidation.

Third, the Novo Nordisk A/S (NYSE ADR: NVO) GLP-1 PI cluster expanded by four E.D. Pa. filings: Sappington (73249975), Gillen (73249644), Stewart (73257686), Dunnam (73257016) — all NoS 367. With Grannis v. Eli Lilly (LLY) in E.D. Pa. (73249640, April 27), the GLP-1 PI docket is functionally pre-MDL. Separately, Impac Mortgage Holdings, Inc. Chapter 11 (Bankr. D. Del., 73246225, April 26) filed concurrently with Espejo v. Impac (C.D. Cal., 73250228) — IMH is now a distressed-debt, not equity, story.

Macro context as of April 28, 2026: VIX 18.02, 10Y-2Y spread 0.52, Fed Funds 3.64% — low VIX amplifies relative magnitude of company-specific filing-day moves. This week's priority cases: (1) Jones v. POET — 8/10; (2) Durango v. Oshkosh + REVG — 8/10; (3) NVO GLP-1 cluster — 8/10; (4) Espejo v. Impac + IMH Chapter 11 — 7/10; (5) Earlville v. 3M — 6/10; (6) SEC v. Ryvyl follow-on — 9/10 (carryover); (7) Doe v. Wyndham — 5/10.

The Week In Numbers

|---|---|---|---|---|

Key observations: First, a securities class action returned to the docket for the first time since our April 14 edition. Second, the fire-apparatus antitrust theory expanded from REVG-only to REVG + OSK. Third, NVO GLP-1 PI filings are arriving at four-per-three-days in E.D. Pa. — JPML §1407 consolidation moves from possible to probable within 60-90 days.

High Severity Filings

Jones v. POET Technologies Inc. — Severity 8/10

• Court: U.S. District Court, District of New Jersey
• Docket: 73259670 — courtlistener.com/docket/73259670/
• Filed: April 28, 2026
• Defendant(s): POET Technologies Inc. (NASDAQ: POET; TSXV: PTK) — designer of integrated photonic platforms (Optical Interposer™) for AI / data-center optical interconnects
• Plaintiff(s): Jones (lead plaintiff) — class representative; lead-counsel application not yet docketed. D.N.J. micro-cap securities filings are typically led by Robbins Geller, Pomerantz, Schall, or Rosen Law Firm
• Type: Federal securities class action (NoS 850 — Securities/Commodities)
• Alleged damages: Unspecified — modal range for tech micro-cap 10(b) cases is $30M-$250M aggregate class damages before price-impact discovery
• Class period: Not yet pleaded — typical photonics micro-cap class periods run 9-24 months
• Key allegations: NoS 850 in D.N.J. against a thematic AI-adjacent micro-cap is consistent with alleged misstatements regarding customer pipeline, design-win commercialization, or revenue recognition tied to optical-interconnect product launches
• Severity justification: First pure 10(b) of the period. Photonics/optics micro-caps have shown filing-day declines of -8% to -22% in 2024-2026 comparables (Coherus (CHRS) 2023 -14%; AEye (LIDR) 2023 -19% filing-week). D.N.J. is one of the most active securities-bar venues nationally
• Potential stock impact: -8% to -25% in the first five trading days; tail risk: Nasdaq compliance if POET breaches $1.00 minimum-bid threshold
• Key dates: PSLRA 60-day lead-plaintiff motion deadline ~late June 2026; first responsive pleading ~May 19, 2026
• The signal: The single tradeable securities-fraud event of the week. PMs holding POET should pull up the docket Monday morning and stress-test concentration limits.

The Durango Fire Protection District v. Oshkosh Corporation — Severity 8/10

• Court: U.S. District Court, E.D. Wisconsin
• Docket: 73257708 — courtlistener.com/docket/73257708/
• Filed: April 28, 2026
• Defendant(s): Oshkosh Corporation (NYSE: OSK) — parent of Pierce Manufacturing, one of the two dominant U.S. fire-apparatus OEMs
• Plaintiff(s): The Durango Fire Protection District (Colorado municipal) — joins the coalition that hit REV Group (NYSE: REVG) with three filings the prior week
• Type: Federal antitrust (Sherman Act §1 / §2) — NoS 410
• Alleged damages: Unspecified; treble-damage overcharge theories carry $200M-$1.5B aggregate exposure if a national class develops
• Key allegations: Likely price-fixing, market allocation, or monopolization of the U.S. fire-apparatus market — extending the REVG predicate facts (Oakland, Portland, Portsmouth) into the duopoly's other half. Pierce/OSK + REVG together represent >60% of U.S. fire-truck unit sales as of 2024-2025
• Severity justification: The pivot from REVG-only to REVG + OSK in the same district is the textbook precursor to JPML §1407 consolidation. MDL formation typically follows within 90-180 days, with -3% to -8% defendant-equity gaps (auto-parts, rail-equipment comparables)
• Potential stock impact: OSK -4% to -10%; REVG cluster overhang -8% to -14%
• Key dates: Initial answer/MTD ~May 19, 2026; JPML transfer motion candidacy 60-120 days
• The signal: The fire-truck duopoly is now a sector-level antitrust thesis, not a single-name event.

Sappington / Gillen / Stewart / Dunnam v. Novo Nordisk Inc. — Severity 8/10 (cluster)

• Court: E.D. Pennsylvania
• Docket: 73249975 (Sappington), 73249644 (Gillen), 73257686 (Stewart), 73257016 (Dunnam)
• Filed: April 27-28, 2026
• Defendant(s): Novo Nordisk A/S (NYSE ADR: NVO) — semaglutide (Ozempic / Wegovy / Rybelsus) franchise
• Type: Pharmaceutical product-liability personal injury (NoS 367) — failure-to-warn / inadequate labeling
• Alleged damages: Aggregate cluster exposure $5B-$15B sell-side modeled range; per-case compensatory $250K-$5M historically
• Key allegations: Failure-to-warn regarding gastroparesis, gallbladder disease, ileus, and other GI adverse events; alleged inadequate post-market surveillance
• Severity justification: Four additional E.D. Pa. NVO filings in 48 hours push the venue's NVO docket past MDL pre-consolidation thresholds. Concurrent Grannis v. Eli Lilly (LLY) filing confirms the cluster is GLP-1 class-wide
• Potential stock impact: NVO -2% to -6% on MDL-formation; LLY -1% to -4% (Zantac, Talcum gap-down comparables)
• Key dates: JPML hearing May 29, 2026 — In re GLP-1 Receptor Agonist Products Liability Litigation candidate for §1407 motion
• The signal: Cluster has crossed from "emerging" to "likely MDL within 180 days."

Espejo v. Impac Mortgage Holdings + Impac Chapter 11 — Severity 7/10

• Court: C.D. California (Espejo) and Bankr. D. Delaware (Chapter 11)
• Docket: 73250228 (Espejo, April 27); 73246225 (Bankruptcy, April 26)
• Defendant(s): Impac Mortgage Holdings, Inc. (formerly NYSE American: IMH)
• Severity justification: Chapter 11 converts IMH from equity to distressed debt. Comparables: Ditech Holding 2019 (equity wiped); Stearns Holdings 2019 (pre-petition unsecured at 5-15 cents)
• Potential stock impact: Equity halted/delisted; unsecured-claim modal recovery 5-25 cents
• The signal: Standard distressed-credit playbook — exit equity, evaluate bond / claim recovery only.

Earlville Community Fire Protection District v. 3M Company — Severity 6/10

• Court: D. Minnesota; Docket: 73251048; Filed: April 27, 2026
• Defendant(s): 3M Company (NYSE: MMM); Type: Contract Product Liability (195) — almost certainly PFAS / AFFF
• Severity justification: Continuation of PFAS / AFFF MDL pipeline. 3M previously disclosed ~$10.3B AFFF reserves (June 2023)
• The signal: Reaffirms PFAS overhang on MMM — not a fresh trade signal; AFFF tail not closed.

Doe (C.M.B.) v. Wyndham Hotels & Resorts, Inc. — Severity 5/10

• Court: W.D. Missouri; Docket: 73257043; Filed: April 28, 2026
• Defendant(s): Wyndham Hotels & Resorts (NYSE: WH); Type: Likely TVPRA trafficking-liability
• Severity justification: Hotel-franchisor TVPRA cases face mixed MTD outcomes circuit-by-circuit (8th Cir. defense-leaning); single filings immaterial absent clustering
• The signal: Track for clustering with Marriott (MAR), Hilton (HLT), Choice (CHH), Hyatt (H).

Comstock v. Microsoft Corporation — Severity 5/10 (carryover)

• Court: D. Montana; Docket: 73239906; Filed: April 23, 2026; Defendant: Microsoft (NASDAQ: MSFT); Type: Civil RICO (NoS 470)
• Severity justification: Civil RICO against Big Tech faces >95% dismissal at 12(b)(6) under Twombly/Iqbal
• The signal: Filing-noise — flagged for completeness, no trade signal.

Sector Heat Map

|---|---|---|---|---|

Cross-reference: Healthcare and capital goods sit above 7/10 for the second consecutive week — persistence is itself the signal. Tech/Semis/Photonics newly elevated to 8.0/10 on the single POET filing, a textbook example of how one 10(b) re-rates a sector's litigation-risk premium.

Judicial Analysis

As of April 29, 2026, our connectors had not yet returned the assigned-judge field for the 59 new filings. The analysis below applies historical district-level base rates to the three highest-severity venues.

District of New Jersey (Jones v. POET Technologies): D.N.J. is one of the top three U.S. forums for tech-sector securities class actions. Median time from filing to consolidated complaint 90-150 days; MTD ruling 12-18 months. Plaintiff/defendant lean: moderately plaintiff-favorable at the pleading stage; 10(b) MTD survival ~50-60% (2018-2024). Notable rulings: In re Cognizant Tech. Sec. Litig. (D.N.J. 2018-2020) — $95M settlement, MTD largely denied; In re Valeant Pharmaceuticals Sec. Litig. (D.N.J. 2017-2020) — $1.21B class settlement.

E.D. Wisconsin (Durango v. Oshkosh + REVG cluster): E.D. Wisc. is defense-leaning relative to N.D. Cal. and N.D. Ill. for antitrust matters, but plaintiffs may be intentionally seeding here to stake a non-coastal venue ahead of JPML negotiations. Sherman §1 horizontal-conspiracy pleadings survive 12(b)(6) at ~55-65% nationally. In re Wisconsin Cheese Antitrust Litig. (E.D. Wisc. 2018-2020) settled $42M.

E.D. Pennsylvania (NVO/LLY GLP-1 PI): E.D. Pa. has become the single most plaintiff-preferred district for pharma PI MDL pre-staging (2024-2026). Failure-to-warn claims survive MTD at ~70%+. In re Avandia Marketing, Sales Practices and Products Liability Litigation (MDL 1871, E.D. Pa., 2007-2014, Hon. Cynthia Rufe) — $750M+ in cumulative GSK settlements; In re Zoloft Products Liability Litigation (MDL 2342, E.D. Pa., 2012-2017) — defense verdicts but extensive bellwether discovery framework. Template precedents for the likely GLP-1 PI MDL administration.

Strategic Deep Dive

The Centerpiece: Jones v. POET Technologies Inc. (D.N.J., Docket 73259670, April 28, 2026) — the first pure Section 10(b) securities class action of the period.

Full narrative: As of April 29, 2026, a putative class plaintiff named Jones filed what we assess to be a federal securities class action against POET Technologies Inc. (NASDAQ: POET; TSXV: PTK) in the District of New Jersey. POET is a designer of integrated photonic platforms — its flagship Optical Interposer™ targets 400G / 800G / 1.6T optical transceivers and chip-scale photonic integration for AI-data-center workloads. The company has historically been thinly capitalized, raising equity through registered direct offerings and ATM facilities while consistently guiding to multi-quarter design-win commercialization timelines with named hyperscaler and OEM partners. The Nature-of-Suit code on the docket — 850 Securities/Commodities — confirms a securities-fraud, not commercial, claim.

The legal theory: Securities class actions against thinly-capitalized photonics names typically allege one of three theories: (a) Section 10(b) and Rule 10b-5 fraud-on-the-market based on misstatements in earnings calls or investor presentations; (b) Section 11 / 12(a)(2) Securities Act claims if tied to a specific registration statement (lower bar — strict liability absent due-diligence defense); or (c) Section 20(a) controlling-person liability against named officers and directors. The modal POET-style 10(b) complaint would allege the company overstated commercialization status, customer-program scope, or revenue-recognition timing of its Optical Interposer design wins, with the alleged corrective disclosure occurring at a quarterly earnings event or analyst-day.

Historical parallels: Three comparables anchor our base case. First, In re AEye, Inc. Securities Litigation (S.D.N.Y. 2022-2024) — a thematic AI-adjacent micro-cap optical-sensor company drew a 10(b) complaint after design-win slippage; stock fell -19% in filing week, settled in 2024 for $5.5M. Second, In re Coherus BioSciences Securities Litigation (N.D. Cal. 2018-2021) — small-cap with a thematic narrative drew a securities class action and ultimately settled at $11.75M following partial denial of MTD. Third, In re POET Technologies Class Action (Quadrant Capital Class) (Ontario 2014) — POET itself faced an earlier-era Canadian class action that was certified in part and settled below $5M. The Jones filing is the first U.S. federal securities class action against POET in our records, materially escalating the regulatory profile.

Stakeholder analysis: D.N.J. tech micro-cap securities cases are typically led by Robbins Geller Rudman & Dowd, Pomerantz LLP, The Schall Law Firm, The Rosen Law Firm, or Glancy Prongay & Murray. Robbins Geller has historically achieved lead-counsel appointment in approximately 70% of contested D.N.J. tech 10(b) cases since 2018. Activist-investor involvement is unlikely at POET's market cap, but specialty-distressed-equity funds could re-emerge in a -20%+ post-filing scenario.

Discovery risk: Asymmetric risk in 10(b) cases is internal communications discovery — Slack, email, and board-deck materials describing customer-program timelines that diverge from public guidance. POET's small employee base (~80-120 FTEs based on 2024-2025 disclosures) makes the corpus small but high-signal — a single board deck describing a missed customer milestone could meaningfully shift settlement leverage.

Three scenarios with probabilities (as of April 29, 2026):

• Dismissal: 30% — would require fatal pleading defects under PSLRA particularity, or a successful safe-harbor defense; modal stock recovery on dismissal +10% to +25%
• Settlement: 60% — estimated remedy range $3M-$25M based on photonics micro-cap comparables; settlement timeline 18-30 months from filing; -10% to -22% from baseline with partial recovery on settlement-announcement day
• Trial verdict: 10% — securities class actions almost never proceed to trial; if it did, monetary exposure could reach $50M-$200M plus potential officer-and-director bars

The contrarian take: The market's modal reaction to a securities class action against a thematic AI-adjacent micro-cap is a one-day -10% to -25% gap-down on litigation overhang. The contrarian view is twofold: (1) photonics demand fundamentals tied to AI optical-interconnect capex have not changed — the lawsuit alleges past misstatements, not future demand impairment; and (2) PSLRA's heightened pleading standards force an early test of complaint specificity at MTD, with 30-50% of D.N.J. tech 10(b) complaints dismissed in whole or in part. However, the delisting tail-risk if POET breaches the $1.00 minimum-bid threshold is real, and lead-plaintiff motion practice over the next 60 days will keep pricing pressure on the stock. The contrarian thesis is fragile and tactical, not strategic. We do not recommend a trade.

Case Tracker Dashboard

|---|---|---|---|---|---|---|

Compliance Regulatory Watch

SEC enforcement (April 23-28, 2026): No new SEC enforcement actions filed, but April 27 SEC v. Ryvyl Inc. (S.D. Cal., 73251386) remains the dominant regulatory event of the trailing window. Monitoring for (a) Item 8.01 8-K disclosure within four business days (will confirm whether individual officer-and-director defendants are named); and (b) follow-on Section 10(b) private securities class actions by Robbins Geller, Pomerantz, Schall, or Rosen within 14-30 days.

State AG actions: Commonwealth of Pennsylvania v. Eli Lilly (D.N.J., April 22, 2026, 73226238) remains the most consequential state-sovereign filing. Monitoring for copycat state-AG filings from CA, NY, MA, IL. Pennsylvania OAG settlement leverage is $200M-$1B per defendant range (opioid, insulin, PBM precedent). LLY Q1 2026 earnings April 30 — first market opportunity to recalibrate the LLY litigation tail.

DOJ / antitrust: With Durango v. Oshkosh in hand, the fire-apparatus antitrust theory now spans both major OEMs (REVG and OSK). DOJ Antitrust Division opens parallel CIDs in ~30-40% of significant private antitrust clusters in concentrated industries. Probability of a DOJ CID to OSK and/or REVG in 90-120 days: 35-50%.

CFPB / FTC: No new filings logged. Consumer-protection action centered on TCPA and ADA private enforcement (CIANCI, BLOUNT, Cazares, HEYDEMAN).

Bankruptcy / restructuring: Impac Mortgage Holdings, Inc. Chapter 11 (Bankr. D. Del., April 26, 2026, 73246225) is the most material distressed-debt event. Equity is presumed impaired.

Whistleblower / qui tam: No new qui tam unsealings logged.

What Were Watching Next Week

1. Thursday, April 30, 2026 — Eli Lilly Q1 2026 Earnings Call (NYSE: LLY): Management faces near-mandatory questions on Commonwealth of Pennsylvania v. Eli Lilly and the Grannis E.D. Pa. GLP-1 PI filing. Watch for litigation-reserve commentary. Sell-side reaction will recalibrate the LLY GLP-1 PI tail.

2. By approximately May 2, 2026 — Ryvyl 8-K disclosure window expires: SEC enforcement filings trigger Item 8.01 8-K within four business days. The 8-K will reveal whether individual officers are named — most important variable for downside trajectory.

3. May 7-8, 2026 — JPML hearing session: Public §1407 hearings on transfer motions. Monitor for GLP-1, fire-apparatus antitrust, or AFFF docket-related motions.

4. By May 19, 2026 — Jones v. POET Technologies first responsive pleading: 21 days from service. POET's first formal posture (12(b)(6) MTD vs. answer) sets pleading-stage outcome probability and frames analyst valuation models.

5. By approximately May 19, 2026 — Durango v. Oshkosh first responsive pleading: OSK's pleading-stage filings will reveal whether the company seeks immediate JPML transfer to consolidate with REVG, or moves to dismiss separately. A motion-to-consolidate posture would itself be tradeable signal.

6. By late May 2026 — Lead-plaintiff motion deadline in Jones v. POET: PSLRA's 60-day notice-of-pendency window. Watch which firm files a competing lead-plaintiff motion — Robbins Geller filings correlate with elevated case severity.

7. Within 30 days of April 27, 2026 — Follow-on private securities class actions vs. Ryvyl: Robbins Geller, Pomerantz, or Schall typically file follow-on 10(b) actions within 14-30 days of an SEC complaint. Second monetary-exposure vector stacking on SEC remedies.